Pediatric Hematology/Oncology (AREKEN) Osaka Univ Grad School Med: June 2009

Tuesday, June 30, 2009

Nature. 2009 Jun 25;459(7250):1126-30.
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S.

N Engl J Med. 2004 Sep 16;351(12):1175-86.
Talking about death with children who have severe malignant disease.
Kreicbergs U, Valdimarsdóttir U, Onelöv E, Henter JI, Steineck G.

Blood. 2009 Jan 22;113(4):775-83.
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.
Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA.

Cancer. 2008 Aug 1;113(3):515-21.
Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).
Arico M, Ziino O, Valsecchi MG, Cazzaniga G, Baronci C, Messina C, Pession A, Santoro N, Basso G, Conter V; Italian Association of Pediatric Hematology and Oncology (AIEOP).

Cancer. 2008 Mar 15;112(6):1345-53.
High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors.
Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M.